Enhancing the Lucentis (Ranibizumab) Management of Choroidal Neovascular Membranes With Hyperspectral Imaging

Center for Eye Research Australia4 enrolled

Overview

Clinical trial investigating the role of hyperspectral imaging in the management of patients undergoing standard clinical treatment for naive neovascular choroidal membranes in age-related macular degeneration.

Observational trial of patients with choroidal neovascular membranes treated with Lucentis. Exploration and validation of a new form of retinal imaging called hyperspectral imaging. Inclusion: Patients meet eligibility criteria other than FFA diagnosis and who are diagnosed with suspected exudative CNV on the OCT. (n=100 eyes) Procedure: Monthly doses of Lucentis. OCT scans will be taken prior to each injection. HSI image taken at baseline and at the 9-month time point. Time frame: 6 months recruitment + 12 months follow-up + 6 months analysis. All recruited patients will receive monthly doses of Lucentis as per the CMBS-approved protocol to allow comparison with other published studies. Lucentis will be administered in accordance with published standards of practice. OCT scans will be taken prior to each injection. HSI image will be taken at baseline, three months and 9-month time points

Study Type

OBSERVATIONAL

Enrollment

Conditions

Macular Degeneration Choroidal Neovascularization

Interventions

Hyperspectral imagingDEVICE

Hyperspectral retinal images will be taken at baseline (before treatment with Lucentis) and then at 3 and 9 months after treatment.

Eligibility

Sex: ALLMin age: 50 YearsMax age: 80 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Provide signed and dated informed consent form * Willing to comply with all study procedures and be available for the duration of the study * Male or female, aged 50-80 * In sufficiently good general health to be able to have a FFA * CNV diagnosed by OCT * Vision equal or better than 6/60 in the study eye * No prior treatment in the study eye with anti-VEGF medication Exclusion Criteria * Significant media opacity. * Known allergic reactions to components of the study product(s). * Anything that would place the individual at increased risk or preclude the individual's full compliance with or completion of the study.

Locations (1)

Centre for Eye Research Australia

East Melbourne, Victoria, Australia

Outcomes

Primary Outcomes

Hyperspectral image characteristics that predict response of choroidal neovascularisation to Lucentis

Hyperspectral images will be analysed to define specific characteristics that identify which types of choroidal neovascularisation will respond to Lucentis. Responsive patients will be differentiated from non-responders and distinguishing image features will be identified.

Time frame: 3-9 months

Secondary Outcomes

Specific spectral signature for identification of exudative AMD

Spectral bands of the HSI containing the most predictive information for diagnosis and treatment response will be characterised.

Time frame: 3-9months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.